6:45 – 8 am
Thursday, September 13

HSCT Complications: A Case-Based Approach to Diagnosing and Treating Veno-Occlusive Disease: Non-CNE Breakfast Symposium (SY1)

The presentation will guide the audience through the patient presentation and history, symptom presentation, differential diagnosis considerations, and progression of VOD. This program’s educational objectives are:

  • Recognizing key risk factors for hepatic VOD
  • Strategies for earlier detection and diagnosis of VOD
  • Review clinical information about a treatment option

Please note that while this optional event is included in the conference fee, selecting the event on the registration form is required to attend. Space is limited. 

jazz homepage

APHON thanks Jazz Pharmaceuticals, Inc. for their generous support of this event.

12:00 – 1:15 pm
Thursday, September 13

ALL Treatment and Considerations Around Asparaginase Hypersensitivity, A Case-Based Approach Non-CNE Lunch Symposium (SY2)

This program will focus on the following topics:

  • Overview of hypersensitivity reactions
  • Primary immune response and immunologic memory
  • Re-challenge and immunogenic reactions
  • Premedication and considerations around masking
  • Antibody effects on drug pharmacokinetics
  • Management of immunogenicity

Please note that while this optional event is included in the conference fee, selecting the event on the registration form is required to attend. Space is limited. 

jazz homepage

APHON thanks Jazz Pharmaceuticals for their generous support of this event.

6:15–6:45 pm
Thursday, September 13

Key Considerations for the Only FDA-Approved oral TPO Receptor Agonist for the Treatment of Chronic ITP in Patients 1 year and Older

While childhood immune thrombocytopenia (ITP) may spontaneously resolve, children who develop chronic ITP are often at significant risk for bleeding and may require treatment. In this program, we will present and discuss treatment options approved for use in pediatric patients with ITP. Objectives include:
  • Discuss the unique activity of an agent in the context of disease pathophysiology
  • Review efficacy and safety data
  • Review dosing and administration



Exhibit Hall Theater
Katie Atkinson, FNP
New York-Presbyterian Hospital
Weill Cornell Medical College
7:15–7:45 pm
Thursday,September 13

AFSTYLA and IDELVION: Challenging the Paradigm in Hemophilia

This program offers you the opportunity to:

  • Discuss current challenges in hemophilia A and B treatment 
  • Explore the features and benefits of both AFSTYLA and IDELVION
  • Discover valuable resources, tools, and support
  • Examine a case-based approach to hemophilia A and B
  • Share experiences, ask questions, and gain valuable information which will enable you to better treat patients with hemophilia A and B

CSL Berring

Exhibit Hall Theater
Claudio Sandoval, MD
1:50–2:20 pm
Friday, September 14

Diagnosing aHUS: A Pediatric Patient Case Journey

Description: Follow along the patient journey as atypical hemolytic uremic syndrome (aHUS) is diagnosed and review of the clinical decisions, supporting information, and clinical data that arise during this journey. The objectives of this talk include:

  • Describing the clinical considerations in the diagnosis of aHUS and distinguish aHUS from other thrombotic microangiopathies (TMA) with similar clinical presentations
  • Increasing the confidence in diagnosing aHUS associated with a complement-amplifying condition and recognize the importance of the ADAMTS13 assay and the timing of that assay
  • Recognizing the limitations of plasma therapy in aHUS
  • Understanding the factors that inform long-term management of patients with aHUS 


Exhibit Hall Theater
Dr. Nirmish Shah, MD
Assistant Professor of Medicine
Division of Hematology
Division of Pediatric Hematology/Oncology
Duke University School of Medicine
4:20–4:50 pm
Friday, September, 14

Care with Confidence: Preparing for your Next High-Risk Neuroblastoma Patient

During this session, we will prepare to educate high-risk neuroblastoma patients and families with confidence, have insightful conversations with providers, and better support one another at the bedside.

Come to learn from each other as we discuss tools and resources to help support you when caring for this patient population.

United Therapeutics

Exhibit Hall Theater
Theresa C. DiSipio, MSN CPNP-AC CPHON®
Saturday, September 15
7:30 – 8:45 am

Healing Hope and the Promise of Healthy Survivorship — Recognition Breakfast for Certified Oncology Nurses* (RB)

Please note that the breakfast has reached the max capacity.

1CNE  Wendy S. Harpham is a doctor of internal medicine, 27-year cancer survivor, best-selling author, nationally recognized speaker and patient advocate. From both sides of the stethoscope, Wendy has used her useful perspective to help patients become Healthy Survivors -- namely, survivors who get good care and live as fully as possible.

Since her diagnosis, Wendy has played an important role in raising awareness among clinicians and in empowering patients to talk with their healthcare team about the challenges of survivorship, such as coping with post-treatment fatigue, raising healthy children when a parent has cancer, and participating in clinical trials.

Wendy S. Harpham, MD
Saturday, September 15
12:45 – 2 pm

Asparaginase Toxicities in ALL: Rapid Identification, Management, and Patient/Family Partnerships to Improve Outcomes (SY3)

Get the latest updates on current and emerging asparaginase therapies in pediatric ALL at this interactive satellite symposium. A variety of topics will be discussed, including mechanism of action and pharmacokinetics, monitoring and management of asparaginase toxicities, and communication approaches specific to pediatric patients and their families. Attendees will have the opportunity to interact with expert faculty throughout the symposium.

Belinda Mandrell, PhD RN

Katie Gettinger, MSN RN CPNP
Anna Lefebvre, MSN RN CPNP CPON®